---
title: "Tardive Dyskinesia"
description: "Clinical decision support for tardive dyskinesia evaluation, prevention, and management"
version: "1.1"
setting: "ED, HOSP, OPD"
status: approved
tags:
  - movement-disorders
  - drug-induced
  - outpatient
  - antipsychotics
---

# Tardive Dyskinesia

**DIAGNOSIS:** Tardive Dyskinesia
**ICD-10:** G24.01 (Drug-induced tardive dyskinesia); G24.02 (Drug-induced acute dystonia); G24.09 (Drug-induced dystonia, unspecified)

**CPT CODES:** 80053 (CMP), 85025 (CBC with differential), 84443 (TSH), 82525 (24-hour urine copper), 82550 (CK), 80299 (Antipsychotic drug level), 81401 (Huntington disease genetic testing, HTT CAG repeats), 85060 (Acanthocyte smear), 86255 (Paraneoplastic antibody panel), 81479 (SLC6A3 genetic testing), 96127 (AIMS — Abnormal Involuntary Movement Scale), 70553 (MRI Brain), 78607 (DaTscan, ioflupane I-123), 78816 (PET scan, FDG or dopamine receptor imaging), 92012 (Slit lamp examination), 95886 (EMG)
**SYNONYMS:** TD, tardive syndrome, tardive movement disorder, persistent tardive syndrome
**SCOPE:** Diagnosis confirmation, severity assessment using AIMS, identification of causative agents, risk factor evaluation, FDA-approved VMAT2 inhibitor therapy, antipsychotic management strategies, prevention, and psychiatric coordination. Covers classic orofacial-lingual TD, tardive dystonia, tardive akathisia, and tardive stereotypy.

**VERSION:** 1.1
**CREATED:** January 27, 2026
**REVISED:** January 30, 2026

**STATUS:** Approved

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## SECTION A: ACTION ITEMS

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| CMP (80053) | STAT | ROUTINE | ROUTINE | STAT | Baseline renal/hepatic function before VMAT2 inhibitor therapy; electrolyte abnormalities can worsen movements | Normal |
| CBC with differential (85025) | STAT | ROUTINE | ROUTINE | STAT | Baseline for medication monitoring; rule out infection if acute change | Normal |
| TSH (84443) | URGENT | ROUTINE | ROUTINE | - | Thyroid dysfunction can cause or exacerbate movement disorders | Normal (0.4-4.0 mIU/L) |
| Medication and dose history review | STAT | ROUTINE | ROUTINE | - | Identify causative agent(s): antipsychotics, metoclopramide, prochlorperazine, other dopamine blockers | Document agent, duration, cumulative dose |

### 1B. Extended Workup (Second-line)

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| Ceruloplasmin, serum copper (82390/82525) | - | EXT | ROUTINE | - | Rule out Wilson's disease if age <50 or atypical presentation | Normal |
| 24-hour urine copper (82525) | - | - | EXT | - | Wilson's disease confirmation if ceruloplasmin low or borderline | <100 μg/24hr |
| Vitamin B12, folate (82607/82746) | - | ROUTINE | ROUTINE | - | Deficiency can cause movement disorders | Normal |
| Iron studies: ferritin, serum iron, TIBC (82728/83540/83550) | - | EXT | ROUTINE | - | Rule out brain iron accumulation disorders | Normal |
| CK (82550) | STAT | STAT | - | STAT | If concern for neuroleptic malignant syndrome or severe dystonia | Normal |
| Antipsychotic drug level (80299) | - | ROUTINE | ROUTINE | - | Assess compliance and toxicity if indicated | Therapeutic range |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| Huntington disease genetic testing, HTT CAG repeats (81401) | - | - | EXT | - | Chorea with psychiatric history; family history | <36 CAG repeats (normal) |
| Acanthocyte smear (85060) | - | - | EXT | - | Neuroacanthocytosis if orofacial dyskinesia with chorea | Negative |
| Paraneoplastic antibody panel (86255) | - | EXT | EXT | - | Atypical movement disorder; occult malignancy; autoimmune chorea | Negative |
| Anti-NMDA receptor antibodies (86255) | - | EXT | EXT | - | Young patient; psychiatric symptoms; orofacial dyskinesia | Negative |
| SLC6A3 genetic testing (81479) | - | - | EXT | - | Research; consider if dopamine transporter dysfunction suspected | Normal |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| AIMS — Abnormal Involuntary Movement Scale (96127) | URGENT | ROUTINE | ROUTINE | - | At evaluation; before treatment; q3-6 months on antipsychotics | Document baseline severity (0-4 scale per item; total score) | None |
| Clinical examination: orofacial, trunk, limbs | STAT | ROUTINE | ROUTINE | - | At evaluation | Characterize movement type, distribution, severity | None |
| Video documentation | - | ROUTINE | ROUTINE | - | At baseline and follow-up | Record for comparison; share with psychiatry | Patient consent |

### 2B. Extended

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| MRI Brain (70553) | URGENT | ROUTINE | ROUTINE | - | Atypical presentation; focal findings; rule out structural lesion | Normal or chronic dopaminergic medication changes | MRI-incompatible devices |
| DaTscan, ioflupane I-123 (78607) | - | - | EXT | - | Differentiate from Parkinson's disease or Huntington's if uncertain | Normal or mild reduction (dopamine blockers can affect) | Iodine hypersensitivity |

### 2C. Rare/Specialized

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| MRI Brain with SWI sequence (70553) | - | EXT | EXT | - | Suspected brain iron accumulation (NBIA) | No abnormal iron deposition | MRI contraindications |
| PET scan, FDG or dopamine receptor imaging (78816) | - | - | EXT | - | Research; atypical cases | Variable | None |
| Slit lamp examination (92012) | - | EXT | EXT | - | Wilson's disease evaluation | No Kayser-Fleischer rings | None |
| EMG (95886) | - | - | EXT | - | Characterize tremor vs dystonic movements | Define movement characteristics | None |

---

## 3. TREATMENT

### 3A. Acute/Emergent

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Discontinue or reduce causative agent | N/A | First step if psychiatrically safe; requires psychiatry coordination | N/A :: N/A :: N/A :: Collaborate with psychiatry; gradual taper preferred if stopping; dose reduction may help | Cannot discontinue if psychosis relapse risk too high | Monitor for psychiatric decompensation | URGENT | URGENT | ROUTINE | URGENT |
| Switch to clozapine | PO | Lowest TD risk; for patients requiring continued antipsychotic | 12.5 mg :: PO :: qHS :: Start 12.5-25 mg/day; titrate by 25-50 mg q3-7d; target 200-450 mg/day; requires REMS | Agranulocytosis history; severe neutropenia; seizure disorder (relative) | ANC weekly x 6mo, q2wk x 6mo, then monthly; seizures; myocarditis | URGENT | URGENT | ROUTINE | - |
| Switch to quetiapine | PO | Lower TD risk; for patients requiring continued antipsychotic | 25 mg :: PO :: BID :: Start 25-50 mg BID; titrate by 50-100 mg/day q2-3d; target 300-800 mg/day | QT prolongation; severe hepatic impairment | QTc, sedation, metabolic parameters | URGENT | URGENT | ROUTINE | - |
| Benzodiazepine (severe distress) | PO/IV | Severe anxiety/distress from TD movements; temporary relief | 0.5 mg :: PO :: TID PRN :: Lorazepam 0.5-1 mg TID PRN for acute distress; short-term only | Respiratory depression; substance use disorder | Sedation, respiratory status | URGENT | URGENT | - | URGENT |

### 3B. Symptomatic Treatments (FDA-Approved for TD)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Valbenazine (Ingrezza) | PO | FDA-approved first-line for TD; VMAT2 inhibitor | 40 mg :: PO :: daily :: Start 40 mg once daily; increase to 80 mg daily after 1 week if tolerated; take with or without food | Congenital long QT; strong CYP2D6 inhibitors at higher dose; severe hepatic impairment | QTc (baseline, after dose increase); somnolence; depression | - | ROUTINE | ROUTINE | - |
| Deutetrabenazine (Austedo) | PO | FDA-approved first-line for TD; VMAT2 inhibitor | 6 mg :: PO :: BID :: Start 6 mg BID (12 mg/day); increase by 6 mg/day weekly; max 48 mg/day; take with food | Depression/suicidality; MAO-I use; hepatic impairment; reserpine use within 20 days | Depression (PHQ-9); parkinsonism; QTc; akathisia | - | ROUTINE | ROUTINE | - |
| Tetrabenazine (Xenazine) | PO | VMAT2 inhibitor; older agent with more side effects | 12.5 mg :: PO :: daily :: Start 12.5 mg daily; increase by 12.5 mg q1wk; max 50 mg/day (100 mg if CYP2D6 extensive metabolizer); require CYP2D6 genotyping >50 mg | Depression/suicidality; untreated or inadequately treated depression | Depression (PHQ-9); parkinsonism; akathisia; sedation; requires CYP2D6 genotyping | - | ROUTINE | ROUTINE | - |

### 3C. Second-line/Refractory

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Clonazepam | PO | Adjunct for TD; limited evidence; reduces choreiform movements | 0.25 mg :: PO :: BID :: Start 0.25 mg BID; titrate slowly; typical 0.5-4 mg/day divided | Respiratory depression; substance use disorder | Sedation, dependence, falls | - | ROUTINE | ROUTINE | - |
| Amantadine | PO | Limited evidence; may reduce TD severity; antiglutamatergic | 100 mg :: PO :: BID :: Start 100 mg BID; may increase to 300-400 mg/day divided; adjust for renal function | Severe renal impairment; seizure history (relative) | Livedo reticularis; edema; hallucinations; confusion (elderly) | - | ROUTINE | ROUTINE | - |
| Ginkgo biloba | PO | Limited evidence; antioxidant mechanism; modest benefit in trials | 120 mg :: PO :: BID :: 240 mg/day divided; EGb 761 extract standardized | Bleeding disorders; anticoagulant use | Bleeding risk | - | - | ROUTINE | - |
| Vitamin E | PO | Limited evidence; may prevent progression; minimal therapeutic effect | 400 IU :: PO :: daily :: 400-1600 IU daily; better evidence for prevention than treatment | Coagulopathy; vitamin K deficiency | Bleeding risk at high doses | - | - | ROUTINE | - |
| Vitamin B6 (pyridoxine) | PO | Limited evidence; some trials show benefit | 100 mg :: PO :: daily :: 100-400 mg daily; monitor for neuropathy at high doses | Peripheral neuropathy | Neuropathy with chronic high dose (>200 mg) | - | - | EXT | - |
| Levetiracetam | PO | Limited evidence; case reports of benefit | 500 mg :: PO :: BID :: Start 500 mg BID; titrate to 1500-3000 mg/day; adjust for renal function | Severe renal impairment without adjustment | Mood changes; sedation | - | - | EXT | - |
| Propranolol | PO | For tardive akathisia component | 10 mg :: PO :: TID :: Start 10 mg TID; titrate to 30-120 mg/day divided | Asthma; bradycardia; heart block | HR, BP | - | ROUTINE | ROUTINE | - |

### 3D. Interventional/Advanced Therapies

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Botulinum toxin (focal TD) | IM | Focal tardive dystonia (e.g., cervical, blepharospasm) | Per target :: IM :: q3mo :: Cervical: 100-300 units; blepharospasm: 25-50 units per eye; repeat q3mo | EMG guidance recommended for some targets | Active infection at site; myasthenia gravis | Dysphagia (cervical); ptosis (periocular); local weakness | - | - | ROUTINE | - |
| Deep brain stimulation (DBS) | Surgical | Severe, disabling, medication-refractory TD | GPi target :: Surgical :: per protocol :: Bilateral GPi most common; programming optimization over months | MRI; neuropsychological testing; multidisciplinary evaluation; psychiatry clearance | Untreated psychiatric instability; cognitive impairment; coagulopathy | Programming; psychiatric monitoring; speech/swallowing | - | - | EXT | - |
| Pallidal lesioning | Surgical | Alternative to DBS if not candidate; irreversible | Unilateral pallidotomy :: Surgical :: per protocol :: Stereotactic lesion of GPi; reserved for DBS failures or contraindications | Same as DBS | Same as DBS | Permanent side effect risk higher than DBS | - | - | EXT | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Psychiatry consultation for antipsychotic management, dose reduction, or switch to lower-risk agent (ESSENTIAL - requires collaborative decision-making) | URGENT | URGENT | ROUTINE | URGENT |
| Movement disorders neurology for diagnosis confirmation, AIMS scoring, and VMAT2 inhibitor initiation | - | ROUTINE | ROUTINE | - |
| Neurosurgery consultation for DBS evaluation if medication-refractory disabling TD | - | - | EXT | - |
| Speech therapy for dysphagia evaluation if oropharyngeal involvement | - | ROUTINE | ROUTINE | - |
| Occupational therapy for adaptive strategies if hand involvement affects function | - | ROUTINE | ROUTINE | - |
| Social work for disability evaluation and resources if TD causes functional impairment | - | - | ROUTINE | - |
| Dentistry for oral health evaluation with orofacial TD (tooth damage, denture issues) | - | - | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Report any worsening movements, difficulty swallowing, or breathing problems immediately (may indicate progression) | ROUTINE | ROUTINE | ROUTINE |
| Do not stop antipsychotic medications without psychiatry guidance as this can worsen psychosis or cause withdrawal dyskinesia | ROUTINE | ROUTINE | ROUTINE |
| Report any new or worsening depression, suicidal thoughts, or mood changes on VMAT2 inhibitors (boxed warning) | - | ROUTINE | ROUTINE |
| Movements may temporarily worsen after stopping causative drug before improving (withdrawal dyskinesia) | ROUTINE | ROUTINE | ROUTINE |
| VMAT2 inhibitors may take 2-6 weeks to show maximum benefit; continue as prescribed | - | ROUTINE | ROUTINE |
| Avoid caffeine and stimulants which may worsen involuntary movements | - | ROUTINE | ROUTINE |
| Maintain regular dental visits for oral health if orofacial TD present (prevents tooth damage, ulceration) | - | - | ROUTINE |
| Consider support groups and counseling for coping with visible movement disorder | - | - | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Use lowest effective antipsychotic dose for shortest duration needed (primary prevention) | - | ROUTINE | ROUTINE |
| Perform AIMS examination at baseline, 3 months, 6 months, then q6-12 months on dopamine-blocking agents | - | ROUTINE | ROUTINE |
| Prefer second-generation antipsychotics over first-generation when clinically appropriate (lower TD risk) | - | ROUTINE | ROUTINE |
| Avoid metoclopramide for >12 weeks; use domperidone or other alternatives when possible (not available in US) | - | ROUTINE | ROUTINE |
| Document informed consent regarding TD risk when starting dopamine-blocking agents | - | ROUTINE | ROUTINE |
| Identify and monitor high-risk patients more frequently: elderly, female, mood disorders, diabetes, longer exposure, higher cumulative dose | - | ROUTINE | ROUTINE |
| Consider early intervention with VMAT2 inhibitors before TD becomes severe and irreversible | - | - | ROUTINE |
| Stress management and adequate sleep may help reduce movement severity | - | ROUTINE | ROUTINE |

---

## SECTION B: REFERENCE

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Huntington disease | Family history; cognitive decline; chorea; CAG expansion | Genetic testing for HTT CAG repeats |
| Sydenham chorea | History of rheumatic fever; anti-streptolysin O; younger patients | ASO titer; echocardiogram |
| Withdrawal dyskinesia | Occurs immediately after stopping dopamine blocker; self-limited (<3 months) | History; timeline (TD persists >3 months) |
| Spontaneous orofacial dyskinesia (elderly) | Elderly without antipsychotic exposure; edentulous | Careful medication history; dental exam |
| Wilson disease | Age <50; Kayser-Fleischer rings; liver disease; psychiatric symptoms | Ceruloplasmin; 24h urine copper; slit lamp |
| Neuroacanthocytosis | Orofacial dyskinesia; chorea; self-mutilation; elevated CK; acanthocytes | Acanthocyte smear; CK; genetic testing |
| Autoimmune chorea (anti-NMDA, anti-LGI1) | Subacute onset; psychiatric symptoms; seizures; encephalopathy | Autoimmune antibody panels; CSF |
| Meige syndrome (primary cranial dystonia) | Blepharospasm and oromandibular dystonia without antipsychotic exposure | Clinical history; no dopamine blocker use |
| Tourette syndrome | Childhood onset; tics (brief, suppressible); premonitory urge | Clinical criteria; onset <18 years |
| Drug-induced acute dystonia | Occurs within days of drug exposure; not persistent | Timeline (acute dystonia is immediate, TD delayed) |
| Parkinson disease dyskinesia | History of Parkinson's; peak-dose or diphasic dyskinesia on levodopa | Clear PD diagnosis; levodopa relationship |
| Hyperthyroidism | Tremor predominant; tachycardia; weight loss; heat intolerance | TSH, free T4 |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| AIMS score | Baseline, 3mo, 6mo, then q6-12mo on antipsychotics | Improvement from baseline (decrease of 2+ points clinically meaningful) | Adjust treatment; consider VMAT2 inhibitor | - | ROUTINE | ROUTINE | - |
| AIMS score on VMAT2 inhibitor | q4-8 weeks until stable, then q3-6mo | 50%+ improvement goal; any improvement beneficial | Optimize dose; consider second agent | - | ROUTINE | ROUTINE | - |
| Depression screen (PHQ-9) | Baseline, 2wk, 4wk, then q3mo on VMAT2 inhibitors | PHQ-9 <5 | Hold VMAT2 inhibitor; psychiatry consultation; consider switch | - | ROUTINE | ROUTINE | - |
| Suicidality assessment | Each visit on VMAT2 inhibitors | No suicidal ideation | Immediate psychiatry referral; hold medication | - | ROUTINE | ROUTINE | - |
| QTc interval | Baseline, after dose increase (valbenazine/deutetrabenazine) | <500 msec | Reduce dose; evaluate medications; electrolytes | - | ROUTINE | ROUTINE | - |
| ANC (if on clozapine) | Weekly x 6mo, q2wk x 6mo, then monthly | ANC >1500/mm3 | Follow REMS protocol for neutropenia | - | ROUTINE | ROUTINE | - |
| Parkinsonism symptoms | Each visit on VMAT2 inhibitors | No new bradykinesia, rigidity, rest tremor | Reduce VMAT2 dose | - | ROUTINE | ROUTINE | - |
| Akathisia | Each visit on VMAT2 inhibitors | No subjective restlessness | Reduce dose; consider propranolol | - | ROUTINE | ROUTINE | - |
| Swallowing function | Each visit with orofacial TD | Normal swallowing | Speech therapy referral; modify diet | - | ROUTINE | ROUTINE | - |
| Functional status | Each visit | Acceptable ADL function | OT referral; treatment intensification | - | ROUTINE | ROUTINE | - |
| Weight and metabolic parameters | q3-6mo on antipsychotics | Stable weight; glucose <126 fasting | Lifestyle modification; consider antipsychotic switch | - | ROUTINE | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge home | Mild-moderate TD; able to manage oral medications; follow-up with neurology and psychiatry arranged; no psychiatric instability |
| Admit to floor | New severe TD with swallowing/respiratory involvement; psychiatric decompensation from medication change; severe dystonic component causing pain/disability; need for expedited workup (suspect alternative diagnosis) |
| Admit to ICU | Respiratory compromise from severe oropharyngeal/laryngeal TD; neuroleptic malignant syndrome; severe tardive dystonia with rhabdomyolysis |
| Outpatient follow-up | Initial: 4-6 weeks for medication titration; Stable: q3-6 months for AIMS monitoring; More frequent if depression risk on VMAT2 inhibitors |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| Valbenazine FDA-approved for TD (KINECT 3) | Class I, Level A | [Hauser et al. Am J Psychiatry 2017](https://pubmed.ncbi.nlm.nih.gov/28320223/) |
| Valbenazine efficacy and safety (KINECT 4) | Class I, Level A | [Factor et al. J Clin Psychiatry 2017](https://pubmed.ncbi.nlm.nih.gov/29141124/) |
| Deutetrabenazine FDA-approved for TD (ARM-TD/AIM-TD) | Class I, Level A | [Anderson et al. JAMA Neurol 2017](https://pubmed.ncbi.nlm.nih.gov/28586827/) |
| Tetrabenazine efficacy for TD | Class II, Level B | [Kenney et al. Expert Rev Neurother 2006](https://pubmed.ncbi.nlm.nih.gov/16466307/) |
| AIMS as standard TD assessment | Class II, Level B | [Guy W. ECDEU Assessment Manual 1976](https://pubmed.ncbi.nlm.nih.gov/1049937/) |
| Clozapine lowest TD risk | Class II, Level B | Correll et al. J Clin Psychiatry 2004 |
| Second-generation antipsychotics lower TD risk than first-generation | Class I, Level A | [Carbon et al. World Psychiatry 2017](https://pubmed.ncbi.nlm.nih.gov/28861457/) |
| Risk factors for TD (age, duration, dose, diabetes) | Class II, Level B | [Woerner et al. J Clin Psychopharmacol 1998](https://pubmed.ncbi.nlm.nih.gov/9812112/) |
| AAN evidence-based guideline for TD treatment | Class I-IV, Level A-U | Bhidayasiri et al. Mov Disord 2018 |
| DBS for medication-refractory TD | Class IV, Level C | [Macerollo et al. J Neurol 2020](https://pubmed.ncbi.nlm.nih.gov/32917824/) |
| Ginkgo biloba modest benefit in TD | Class II, Level B | [Zhang et al. J Clin Psychiatry 2011](https://pubmed.ncbi.nlm.nih.gov/20868638/) |
| Vitamin E for TD prevention (not treatment) | Class II, Level U | [Soares-Weiser et al. Cochrane 2018](https://pubmed.ncbi.nlm.nih.gov/29552749/) |
| Clonazepam for TD | Class IV, Level U | [Thaker et al. Acta Psychiatr Scand 1990](https://pubmed.ncbi.nlm.nih.gov/2222138/) |
| Metoclopramide black box warning (>12 weeks increases TD risk) | Regulatory guidance | [FDA Drug Safety Communication 2009](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-and-risk-mitigation-strategy-metoclopramide-containing-drugs) |

---

## CHANGE LOG

**v1.1 (January 30, 2026)**
- Standardized lab tables: reordered columns to `Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding`
- Added CPT codes to all lab tests (1A: 4 rows, 1B: 6 rows, 1C: 5 rows)
- Standardized imaging tables: reordered columns to `Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications`
- Added CPT codes to all imaging studies (2A: 3 rows, 2B: 2 rows, 2C: 4 rows)
- Fixed structured dosing first fields across all treatment sections (3A-3D): starting dose only in first field
- Added VERSION/CREATED/REVISED header block

**v1.0 (January 27, 2026)**
- Initial template creation
- Comprehensive coverage of VMAT2 inhibitors (valbenazine, deutetrabenazine, tetrabenazine)
- AIMS scoring guidance for monitoring
- Risk factor identification and prevention strategies
- Psychiatry coordination emphasized throughout
- Causative agent documentation (antipsychotics, metoclopramide, prochlorperazine)
- Structured dosing format for order sentence generation
- Advanced interventions (DBS, botulinum toxin)

---

## APPENDIX A: AIMS (Abnormal Involuntary Movement Scale) Examination

### Examination Procedure

1. **Patient Preparation:**
   - Patient seated in hard chair without arms
   - Observe at rest, then during activation maneuvers
   - Examine with dentures in and out (if applicable)

2. **Rating Scale:**
   - 0 = None
   - 1 = Minimal, may be extreme normal
   - 2 = Mild
   - 3 = Moderate
   - 4 = Severe

3. **Body Areas Assessed:**

| Item | Body Area | Observation |
|------|-----------|-------------|
| 1 | Muscles of facial expression | Forehead, eyebrows, periorbital area, cheeks |
| 2 | Lips and perioral area | Puckering, pouting, smacking |
| 3 | Jaw | Lateral movement, clenching, chewing, opening |
| 4 | Tongue | Protrusion, tremor, choreoathetoid movement |
| 5 | Upper extremities | Arms, wrists, hands, fingers |
| 6 | Lower extremities | Legs, knees, ankles, toes |
| 7 | Trunk | Neck, shoulders, hips |

4. **Global Judgments:**

| Item | Assessment |
|------|------------|
| 8 | Severity of abnormal movements overall |
| 9 | Incapacitation due to abnormal movements |
| 10 | Patient's awareness of abnormal movements |

5. **Dental Status:**
   - Current dental problems (Y/N)
   - Dentures used (Y/N)

### Interpretation

| Total Score (Items 1-7) | Interpretation |
|------------------------|----------------|
| 0-1 | No or minimal TD |
| 2-4 | Mild TD |
| 5-9 | Moderate TD |
| 10-28 | Severe TD |

### Monitoring Schedule

| Context | AIMS Frequency |
|---------|----------------|
| Starting antipsychotic | Baseline, 3 months, 6 months |
| Stable on antipsychotic | Every 6-12 months |
| On VMAT2 inhibitor | Every 4-8 weeks until stable, then every 3-6 months |
| High-risk patient | Every 3 months |

---

## APPENDIX B: Causative Agents and Risk Factors

### High-Risk Dopamine-Blocking Agents

| Agent Class | Examples | TD Risk Level |
|-------------|----------|---------------|
| First-generation antipsychotics (typical) | Haloperidol, fluphenazine, perphenazine, chlorpromazine | HIGH |
| Metoclopramide | Reglan | HIGH (especially >12 weeks) |
| Prochlorperazine | Compazine | HIGH |
| Promethazine | Phenergan | MODERATE |

### Lower-Risk Antipsychotics

| Agent | TD Risk Level | Notes |
|-------|---------------|-------|
| Clozapine | LOWEST | REMS required; consider for refractory TD |
| Quetiapine | LOW | Good alternative; sedation may be limiting |
| Aripiprazole | LOW | Partial agonist; may worsen TD in some |
| Ziprasidone | LOW | QTc monitoring required |
| Olanzapine | MODERATE | Metabolic concerns |
| Risperidone | MODERATE | Higher than other SGAs |

### Risk Factors for TD Development

| Risk Factor | Relative Risk | Notes |
|-------------|---------------|-------|
| Age >55 years | HIGH | Most important risk factor |
| Female sex | MODERATE | Especially postmenopausal |
| African American ancestry | MODERATE | Higher incidence observed |
| Mood disorder (vs schizophrenia) | MODERATE | Higher risk in bipolar/depression |
| Diabetes mellitus | MODERATE | Metabolic dysfunction |
| Longer duration of exposure | HIGH | Cumulative risk |
| Higher cumulative dose | HIGH | Dose-dependent |
| Intermittent antipsychotic use | MODERATE | Drug holidays may increase risk |
| Early extrapyramidal symptoms | MODERATE | Predictor of TD susceptibility |
| Cognitive impairment | MODERATE | May mask early symptoms |
| Substance use disorder | MODERATE | Especially alcohol |
